United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2013_register executive 2013-02-06 article Notices D09002ee1c7fbe2cd D09002ee1c7fbe389 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency The National Center for Advancing Translational Sciences (NCATS), the National Institutes of Health (NIH), is seeking Cooperative Research and Development Agreement (CRADA) partners to collaborate in the final stages of lead optimization, in vitro and in vivo evaluation, and preclinical development of a novel series of potent, selective, and orally bioavailable small molecule agonists of the relaxin hormone receptor, RXFP1, for the treatment of heart failure and fibrosis. Interested potential CRADA collaborators will receive detailed information on the current status of the project after signing a confidentiality disclosure agreement (CDA) with NCATS. 78 FR 8544 https://www.govinfo.gov/app/details/FR-2013-02-06/2013-02611 2013-02611 fr06fe13-82 4140-01-P https://www.govinfo.gov/app/details/FR-2013-02-06/2013-02611 https://www.govinfo.gov/content/pkg/FR-2013-02-06/html/2013-02611.htm https://www.govinfo.gov/content/pkg/FR-2013-02-06/pdf/2013-02611.pdf 3 p. 8544 8546 78 FR 8544 National Center for Advancing Translational Sciences (NCATS): Cooperative Research and Development Agreement (CRADA) and Licensing Opportunity for Small Molecule Agonists of the Relaxin Hormone Receptor (RXFP1) for Treatment of Heart Failure and Fibrosis; Federal Register Vol. 78, Issue NOTICE 2013-02611 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2013-03-08 4140-01-P 2013-02611

The National Center for Advancing Translational Sciences (NCATS), the National Institutes of Health (NIH), is seeking Cooperative Research and Development Agreement (CRADA) partners to collaborate in the final stages of lead optimization, in vitro and in vivo evaluation, and preclinical development of a novel series of potent, selective, and orally bioavailable small molecule agonists of the relaxin hormone receptor, RXFP1, for the treatment of heart failure and fibrosis. Interested potential CRADA collaborators will receive detailed information on the current status of the project after signing a confidentiality disclosure agreement (CDA) with NCATS.

Interested candidate partners must submit a statement of interest and capability to the NCATS point of contact before March 8, 2013 for consideration. Guidelines for the preparation of a full CRADA proposal will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. CRADA applications submitted after the due date may be considered if a suitable CRADA collaborator has not been identified by NIH among the initial pool of respondents. Licensing of background technology related to this CRADA opportunity is also available to potential collaborators. Further details of this CRADA opportunity and statement of interest please contact Lili Portilla, M.P.A., Acting Director, Office of Policy, Communications and Strategic Alliances, National Center for Advancing Translational Sciences, NIH, 6701 Democracy Blvd., Suite 900, Bethesda, MD 20892-4874; Telephone: (301) 402-0304; E-Mail: lilip@nih.gov or Dr. Krishnan Balakrishnan, Technology Transfer Manager, NCATS, Telephone: (301) 217-2336; Email: balakrik@mail.nih.gov. Cooperative Research and Development Agreements and Licensing Opportunities: Small Molecule Agonists of Relaxin Hormone Receptor for Treatment of Heart Failure and Fibrosis , balakrik@mail.nih.gov lauren.nguyen-antczak@nih.gov lilip@nih.gov Vol. 78, no. 25 Office of the Federal Register, National Archives and Records Administration 2013-02-06 continuing daily deposited born digital 618 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2013-02-06 P0b002ee183c86a95 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr06fe13 https://www.govinfo.gov/app/details/FR-2013-02-06 https://www.govinfo.gov/content/pkg/FR-2013-02-06/pdf/FR-2013-02-06.pdf https://www.govinfo.gov/content/pkg/FR-2013-02-06/xml/FR-2013-02-06.xml fdlp 8345 8955 DGPO 2013-02-06 2024-06-03 FR-2013-02-06 machine generated eng FR FR-2013-02-06 78 25